Funding and Investment - Alamar Biosciences, Inc. closed an oversubscribed convertible notes financing, raising over $50 million in new capital, with participation from new investors T. Rowe Price Investment Management, Inc. and Braidwell LP, alongside existing investors like Illumina Ventures and Sands Capital [1][2] - The financing will support the commercial advancement of Alamar's precision proteomics platform, aimed at enhancing early disease detection [1][2] Leadership and Board Expansion - Dr. Stephen Williams has been appointed as Chief Scientific Officer, bringing over 30 years of experience in precision medicine and biomarker innovation [7] - Rebecca Chambers and Dr. Frank Witney have been appointed to the board of directors, contributing extensive financial and life sciences leadership experience [8][9] - The leadership team expansion is intended to support Alamar's growth and commitment to operational excellence [6][9] Company Overview - Alamar Biosciences is focused on precision proteomics to enable early disease detection, utilizing proprietary NULISA™ technology and the ARGO™ HT System for ultra-high sensitivity [12]